Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 13 - Sep 18
health biotech news today obesity drugs glp-1 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option GLP-1 and the kidney: Medication:Tirzepatide (GLP-1 + GIP) reduce body fat
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology
Cigna subsidiary to cap employer spending on GLP-1s Executives said the move will offer plans and employers “greater predictability and control.” • less than 3 min read Cigna will cap how much employers and health plans spend on GLP-1s—diabetes drugs that have become popular weight loss options despite their hefty price tags—company executives announced Thursday
reduce body fat
Medication:Tirzepatide (GLP-1 + GIP)
To learn more, visit our Review Methodology page
